Big Pharma is placing a high-stakes bet with its new focus on specialization.
With the pressure on to fill looming revenue gaps from patent expirations, the industry’s largest players are moving away from trying to be everything to everyone and zeroing in on areas where they excel. The strategy is designed to help companies weather the coming “financial superstorm,” expected between now and 2030, said Michael Abrams, managing partner at Numerof & Associates.
“So much of their revenue is going to be at risk because of [loss of exclusivity],” he said, adding that the Inflation Reduction Act also effectively shortens the earning life of top drugs.
For example, AstraZeneca is homing in on nucleic acid-based drugs, which show potential in cancer, neuromuscular diseases and bacterial infections. Roche, meanwhile, is investing in the neuro space with its brain shuttle technology, designed to help drugs cross the blood-brain barrier.
Sharpening pipelines offers advantages. The approach can make companies more nimble, prevent them from becoming spread too thin and can offer a competitive advantage in an era of increasing scientific complexity.
But the strategy also confers a heaping amount of risk.
“The choice that they're making is to double down on the riskiest part of the business,” Abrams said.
The upsides of specialization
The decision to pivot toward more specialized pipelines has become increasingly common among the biggest pharma companies as they work to keep pace with a changing landscape, Abrams said.
Not only are companies facing patent cliffs, they’re also confronting a push from the Trump administration to adopt most-favored nation pricing and other cost-reduction measures.
“It’s really not a surprise that the major companies started asking themselves, ‘Can we just hunker down and do what we’ve always done and hope it’ll all come out OK?’ The answer to that one, apparently, was no,” Abrams said.
One potential advantage of this specialized approach is speed, Abrams said.
“This is really all about finding the right balance between breadth and depth."
Michael Abrams
Managing partner, Numerof & Associates
“The IRA and these other things shorten the earning life of their products, which demands that they get through the development process faster and that they increase the odds of success,” he said.
The longer a drug takes getting to market, the less time companies have to make money with it, Abrams said.
“They need to speed up the process. They need to lower their costs,” Abrams said, noting that a more targeted pipeline can help them achieve that.
Specialization also allows companies to trim corporate fat. For example, multiple decentralized divisions often lead to communication breakdowns, while streamlining eliminates organizational noise that can act as a barrier to progress, Abrams said.
“What they're doing, structurally, addresses some of the problems that have plagued these organizations for years,” he said.
And because the science of drug development is becoming more complex, it often makes more sense to buy potential products and expertise rather than developing them entirely in-house. To this end, drugmakers are increasingly licensing or acquiring promising assets from smaller biotechs.
“If you have deeper expertise, you make progress faster, you get to market faster, and you have more time to make money,” Abrams said.
Fewer bets, higher stakes
Specializing is not without its downsides. Whittling down a portfolio means less padding to cushion a blow.
“If you have a failed trial and the product that you were counting on dies, you have fewer places to turn for revenue to make up the deficit,” Abrams said.
A major setback for a leading firm might dramatically its illustrate vulnerability.
“The first time that a market leader in a therapeutic area is betting heavily on a product in development, and it blows up, the stock's going to take a deeper hit than it would have if it were the same company that it was five years ago,” he added.
Specialization also poses risks for the overall market, as many companies converge around the same high-value disease categories.
“They call it a surfeit of riches. You have several companies coming up with the answer to a serious health problem all at once, but it's not great from the point of view of return on investment,” he said.
This environment can quickly devolve into a “me-too” drug market.
“All the people who write the checks can pretty much see what's coming, and they're going to recognize that the first one that comes to them will be followed by the second one shortly after. So, they're not going to put all their eggs in one basket,” he said. “It changes the competitive picture dramatically.”
With most of the attention going to therapeutic areas that have the biggest payback potential, other areas will get less, creating gaps for patients.
This type of highly specialized market also has the potential to drive up acquisition costs, Abrams said. Companies are increasingly sourcing their pipelines from small biotech startups, which are proliferating rapidly. A recent Citeline report showed that the number of small companies with just one or two drugs in their portfolios skyrocketed to over 4,000 in early 2026. China has become a prime source for new drug assets, with out-licensing deals reaching a record $137.7 billion in 2025. But as more companies rely on this ecosystem of small startups, the competition could raise prices.
“The Big Pharma companies will be competing with each other to purchase promising molecules, and that could raise their acquisition costs,” Abrams said. This is already unfolding in China, where the average upfront payment associated with deals rose to $141 million between 2024 and 2025.
For investors, this shifting landscape also complicates decisions about where to invest in drug development.
“If the risk is getting higher and the anticipated revenues are getting smaller, what does that do for the investment rationale for the pharma industry?” Abrams said. “If I'm an investor and I'm going to take more risk, I want a shot at a bigger payout than when I was taking less risk. But I don’t see it.”
Ultimately, whether the strategy succeeds may depend on if it can truly deliver faster, cheaper drug development or if it simply concentrates risk into fewer shots on goal.
“This is really all about finding the right balance between breadth and depth,” Abrams said, adding that time will tell if the approach pays off.
“I think there's no way to answer the question of whether this is a good idea,” Abrams said. “But try it, and if they get what they want in terms of making faster progress and getting to market for less money and in less time, that will be a very important outcome in today's environment.”
